伴淋系抗原表达的急性髓系白血病特点及临床意义
|
摘要
目的探讨急性髓系白血病(acute myeloid leukemia,AML)中淋系抗原表达的特点及临床意义。方法应用流式细胞术(flow cytometry,FCM)检测106例初诊AML患者的免疫表型。结果①106例AML中伴淋系抗原表达者占58.49%(62/106)。②CD56+AML、Ly≥2+AML的完全缓解(complete remission,CR)率及无复发生存期(relapse free survival,RFS)与Ly-AML比较,均有显著性差异(P<0.05)。③CD7+AML、CD19+AML的CR率及RFS与Ly-AML组比较,均无显著性差异(P>0.05)。结论伴有CD56表达或多个淋系抗原表达的AML预后较差。
Objective To study the feature of lymphoid lineage antigen in acute myeloid leukemia(AML) and its clinical significance.Methods Immunophenotype was performed in 106AML patients by three-color flow cytometry.Results ①In 106 cases of AML,the positive rate of lymphoid antigen was 58.49%(62 /106).②CR ratio and RFS of CD56+AML and Ly≥2+AML patients had significant difference when compared with Ly-AML patients(P <0.05).③CR ratio and RFS of CD7+AML and CD19+AML patients had no significant difference when compared with Ly-AML patients(P > 0.05).Conclusion CD56+AML and Ly≥2+AML have bad prognosis.
Objective To study the feature of lymphoid lineage antigen in acute myeloid leukemia(AML) and its clinical significance.Methods Immunophenotype was performed in 106AML patients by three-color flow cytometry.Results ①In 106 cases of AML,the positive rate of lymphoid antigen was 58.49%(62 /106).②CR ratio and RFS of CD56+AML and Ly≥2+AML patients had significant difference when compared with Ly-AML patients(P <0.05).③CR ratio and RFS of CD7+AML and CD19+AML patients had no significant difference when compared with Ly-AML patients(P > 0.05).Conclusion CD56+AML and Ly≥2+AML have bad prognosis.
引文
[1]张之南,沈悌.血液病诊断及疗效标准[M].北京:科学出版社,2007:131-134.
[2]吴伟林,梁建英,朱明清,等.伴髓系抗原表达的急性淋巴细胞白血病MIC分型特征分析[J].中华血液学杂志,2007,28(11):754-756.
[3]Del Poeta G,Stasi R,Venditti A,et al.CD7 expression in acute myeloid leukemia[J].Blood,1993,82(9):2929-2931.
[4]Chang H,Brandwein J,Yi QL,et al.Extramedullary infiltrates of AML are associated with CD56 expression,11q23 abnormalities and inferior clinical outcome[J].Leuk Res,2004,28(10):1007-1011..
[5]Ferrara F,Morabito F,Maetino B,et al.CD56 expression is anindicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy[J].Clin Oncol,2000,18(6):1295-1300.
[6]Raspadori D,Damian D,Lenoic M,et al.CD56 antigen expression in actue myeloid leukemia identifies patients with poor clinical prognosis[J].Leukemia,2001,15(8):1161-1164.
[7]Kojima H,Bai A,Mukai HY,et al.Chronic myelomonocytic leukemia derived from a possible common progenitor of monocytes and natural killer cells[J].Leuk Lymphoma,2000,37(5):617-621.
[8]郭新红,尼丹.急性髓细胞白血病淋系分化抗原表达及临床意义[J].中国实验血液学杂志,2004,12(3):329-331.
[2]吴伟林,梁建英,朱明清,等.伴髓系抗原表达的急性淋巴细胞白血病MIC分型特征分析[J].中华血液学杂志,2007,28(11):754-756.
[3]Del Poeta G,Stasi R,Venditti A,et al.CD7 expression in acute myeloid leukemia[J].Blood,1993,82(9):2929-2931.
[4]Chang H,Brandwein J,Yi QL,et al.Extramedullary infiltrates of AML are associated with CD56 expression,11q23 abnormalities and inferior clinical outcome[J].Leuk Res,2004,28(10):1007-1011..
[5]Ferrara F,Morabito F,Maetino B,et al.CD56 expression is anindicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy[J].Clin Oncol,2000,18(6):1295-1300.
[6]Raspadori D,Damian D,Lenoic M,et al.CD56 antigen expression in actue myeloid leukemia identifies patients with poor clinical prognosis[J].Leukemia,2001,15(8):1161-1164.
[7]Kojima H,Bai A,Mukai HY,et al.Chronic myelomonocytic leukemia derived from a possible common progenitor of monocytes and natural killer cells[J].Leuk Lymphoma,2000,37(5):617-621.
[8]郭新红,尼丹.急性髓细胞白血病淋系分化抗原表达及临床意义[J].中国实验血液学杂志,2004,12(3):329-331.